Floatz logo

131 assets in Esophageal Cancer

Therapeutic assets addressing Esophageal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Amxt1501
Esophageal Cancer
Aminex Therapeutics, Inc.P1/2CC (41)
aur106
Esophageal Cancer
Aurigene Discovery Technologies LimitedP1CC (41)
Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)-
Esophageal Cancer
VM Oncology, LLCP1/2CC (41)
Crpa1A2
Esophageal Cancer
Corregene Biotechnology Co., LtdP1CC (41)
Dexasone
Esophageal Cancer
TakedaP1/2CC (41)
Ebnk-001
Esophageal Cancer
Essen BiotechP1/2CC (41)
Eflornithine
Esophageal Cancer
Aminex Therapeutics, Inc.P1/2CC (41)
Fruquintinib
Esophageal Cancer
Immunitas TherapeuticsP1/2CC (41)
Gotistobart
Esophageal Cancer
OncoC4, Inc.P1/2CC (41)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-23*01 (96.9%) -(Ighd) -Ighj4*01 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (94.7%) -Igkj4*01 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated
Esophageal Cancer
Immunitas TherapeuticsP1/2CC (41)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Esophageal Cancer
Sensei Biotherapeutics, Inc.P1/2CC (41)
Interleukin-15
Esophageal Cancer
Essen BiotechP1/2CC (41)
Ipilimumab
Esophageal Cancer
Neonc Technologies, Inc.P1/2CC (41)
Mdna11
Esophageal Cancer
Medicenna Therapeutics, Inc.P1/2CC (41)
mdx2001
Esophageal Cancer
ModeX Therapeutics, An OPKO Health CompanyP1/2CC (41)
mt-4561
Esophageal Cancer
Tanabe Pharma America, Inc.P1/2CC (41)
neo212
Esophageal Cancer
Neonc Technologies, Inc.P1/2CC (41)
ngm707
Esophageal Cancer
NGM Biopharmaceuticals, IncP1/2CC (41)
Petosemtamab
Esophageal Cancer
Merus B.V.P1/2CC (41)
q702
Esophageal Cancer
Qurient Co., Ltd.P1/2CC (41)
Regorafenib
Esophageal Cancer
Neonc Technologies, Inc.P1/2CC (41)
Ropidoxuridine
Esophageal Cancer
National Cancer Institute (NCI)P1CC (41)
SL-28
Esophageal Cancer
Second Life TherapeuticsP1/2CC (41)
Solnerstotug
Esophageal Cancer
Sensei Biotherapeutics, Inc.P1/2CC (41)
Tak-500
Esophageal Cancer
TakedaP1/2CC (41)
Tcr-T Cells
Esophageal Cancer
Beijing Geekgene Technology Co., LTDP1/2CC (41)
Tocilizumab
Esophageal Cancer
TakedaP1/2CC (41)
Cdx-585
Esophageal Cancer
Celldex TherapeuticsP1CC (40)
NC 410
Esophageal Cancer
NextCure, Inc.P1/2CC (40)
Zimberelimab
Esophageal Cancer
Arcus Biosciences, Inc.P1CC (40)
PRT1419
Esophageal Cancer
Prelude TherapeuticsP1C (39)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW)
Esophageal Cancer
Lumicell, Inc.P1/2C (37)
ab598
Esophageal Cancer
Arcus Biosciences, Inc.P1C (37)
ai-061
Esophageal Cancer
OncoC4, Inc.P1C (37)
Alpaloritovorelli Antibodies
Esophageal Cancer
Anhui Provincial HospitalP1C (37)
Apg 2449
Esophageal Cancer
Ascentage Pharma Group Inc.P1C (37)
Autologous Cd3+ Enriched T Lymphocytes Obtained From Peripheral Blood Mononuclear Cells (Pbmcs) By Apheresis. The Cells Are Transduced With A Self-Inactivating, Non-Replicating Lentiviral Vector Encoding An Enhanced-Affinity T Cell Receptor (Tcr) Targeting The Hla-A*02:01-Restricted Mage-A4 Peptide (Gvydgrehtv) Alongside The Cd8 Alpha (Cd8?) Co-Receptor. The Expressed Transgene Comprises The Coding Sequence For The Cd8? Co-Receptor, Separated By A Foot-And-Mouth Disease Virus 2A Self-Cleaving Peptide Sequence From The Coding Sequence Of The Mage-A4 T-Cell Receptor Alpha And Beta Chains That Are Separated From Each Other By A Porcine Teschovirus-1 2A Self-Cleaving Peptide Sequence, Under Control Of The Human Elongation Factor 1 Alpha (Ef-1?) Promoter. The Construct Is Flanked By 5' And 3' Long Terminal Repeats (Ltrs) And Also Contains A Trna Primer Binding Site, A ? Packaging Signal, A Truncated Gag, A Rev Response Element (Rre) And A Central Polypurine Tract (Cppt) Sequence 5' To The Transgene, And A Polypurine Tract (Ppt) 3' To The Transgene. The Vector Is Pseudotyped With The Vesicular Stomatitis Virus (Vsv) G Envelope Glycoprotein. The Cd3+ T Lymphocytes Are Purified And Activated Using Anti-Cd3/Anti-Cd28 Monoclonal Antibody Coated Magnetic Beads. The Cells Are Then Cultured In Media Containing Interleukin 2 (Il-2), Human Ab Serum And A Protein Kinase B (Akt Inhibitor). The Cells Are Cd3+ (> 80%), Express The High Affinity Mage-A4 Specific Tcr And Cd8? Co-Receptor (Cd8? +Tcr+; >16%) And Are Cytotoxic To Mage-A4 Expressing Tumor Cells
Esophageal Cancer
USWM CT, LLCP1C (37)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells
Esophageal Cancer
USWM CT, LLCP1C (37)
Bl-M07D1
Esophageal Cancer
SystImmune Inc.P1C (37)
Bl-M17D1
Esophageal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.P1C (37)
Brodalumab
Esophageal Cancer
Brian Henick, MDP1C (37)
Cadvec
Esophageal Cancer
Baylor College of MedicineP1C (37)
Cea Car-T Cells
Esophageal Cancer
Chongqing Precision Biotech Co., LtdP1C (37)
Futibatinib
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.P1C (37)
[Ga-68]-Pnt6555
Esophageal Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyP1C (37)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-23*01 (81.6%) -(Ighd) -Ighj3*02 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg1*03V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-33*01 (87.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
Esophageal Cancer
Genentech, Inc.P1C (37)
Idov-Immune
Esophageal Cancer
ViroMissile, Inc.P1C (37)
im-1617
Esophageal Cancer
Immunome, Inc.P1C (37)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-48*01 (90.8%) -(Ighd) -Ighj4*01 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg1*01, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-16*01 (89.5%) -Igkj4*01 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa
Esophageal Cancer
Taiho Pharmaceutical Co., Ltd.P1C (37)
Larotinib
Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.P1C (37)
Showing 51 to 100 of 131 assets
PreviousPage 2 of 3Next